Press releases

Receive e-mail alerts

Internal link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
May 31, 2017 at 11:00 AM UTC
Internal link ProQR Announces Results for the First Quarter of 2017
May 17, 2017 at 11:00 AM UTC
Internal link ProQR remembers co-founder Henri Termeer after his unexpected passing
May 15, 2017 at 11:00 AM UTC
Internal link ProQR Announces R&D Day in New York on June 15
May 09, 2017 at 11:00 AM UTC
Internal link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 at 11:00 AM UTC
Internal link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
April 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at the Deutsche Bank Health Care Conference
April 20, 2017 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 10, 2017 at 11:00 AM UTC
Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
April 03, 2017 at 11:00 AM UTC
Internal link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
March 27, 2017 at 11:00 AM UTC
Internal link ProQR to Present at Two Upcoming Investor Conferences in March
March 01, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
February 28, 2017 at 12:00 PM UTC
Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
February 27, 2017 at 12:00 PM UTC
Internal link ProQR to Present at the LEERINK Partners Global Healthcare Conference
February 07, 2017 at 12:00 PM UTC
Internal link ProQR Announces R&D Day and Provides Update on Innovation Portfolio
November 30, 2015 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
November 23, 2015 at 11:30 AM UTC
Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences
October 01, 2015 at 11:00 AM UTC
Internal link ProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable
September 23, 2015 at 11:00 AM UTC
Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment
September 14, 2015 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2015
August 19, 2015 at 11:59 AM UTC
Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients
June 26, 2015 at 11:54 AM UTC
Internal link ProQR to Present at the JMP Securities Life Science Conference
June 16, 2015 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Results for the First Quarter of 2015
May 21, 2015 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Annual Shareholder Meeting
April 29, 2015 at 11:00 AM UTC
Internal link ProQR to Present at Two Upcoming Investor Conferences in May
April 29, 2015 at 11:00 AM UTC

Press releases

Internal link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

Internal link ProQR Announces Results for the First Quarter of 2017

Internal link ProQR remembers co-founder Henri Termeer after his unexpected passing

Internal link ProQR Announces R&D Day in New York on June 15

Internal link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Internal link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

Internal link ProQR to Present at the Deutsche Bank Health Care Conference

Internal link ProQR Announces Annual Meeting of Shareholders

Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU

Internal link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

Internal link ProQR to Present at Two Upcoming Investor Conferences in March

Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

Internal link ProQR to Present at the LEERINK Partners Global Healthcare Conference

Internal link ProQR Announces R&D Day and Provides Update on Innovation Portfolio

Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials

Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences

Internal link ProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable

Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment

Internal link ProQR Announces Results for the Second Quarter of 2015

Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients

Internal link ProQR to Present at the JMP Securities Life Science Conference

Internal link ProQR Therapeutics Announces Results for the First Quarter of 2015

Internal link ProQR Therapeutics Announces Annual Shareholder Meeting

Internal link ProQR to Present at Two Upcoming Investor Conferences in May